| 1 | Myxoma | 48.4% |
| 2 | Neoplasms, Bone Tissue | 48.4% |
| 3 | Neoplasms, Fibrous Tissue | 48.4% |
| 4 | Giant Cell Tumor of Bone | 47.9% |
| 5 | Chondrosarcoma | 47.3% |
| 6 | synovial sarcoma | 47.3% |
| 7 | Clear Cell Sarcoma of Soft Tissue | 47.3% |
| 8 | Fibrosarcoma | 39% |
| 9 | Osteosarcoma | 39% |
| 10 | fibroma | 36% |
| 11 | Fibromatosis | 36% |
| 12 | Osteoblastoma | 36% |
| 13 | Osteoma | 36% |
| 14 | Malignant Fibrous Histiocytoma | 34.9% |
| 15 | Sarcoma | 34.4% |
| 16 | Dermatofibrosarcoma | 31% |
| 17 | Dermatofibrosarcoma Protuberans | 31% |
| 18 | leiomyosarcoma | 30.1% |
| 19 | liposarcoma | 30.1% |
| 20 | Angiomyolipoma | 30.1% |
| 21 | Alveolar Soft Part Sarcoma | 30.1% |
| 22 | Fibromatosis, Aggressive | 29.9% |
| 23 | Fibromatosis, Abdominal | 29.9% |
| 24 | Adenofibroma | 26.4% |
| 25 | Fibroadenoma | 26.4% |
| 26 | leukemia | 25.4% |
| 27 | Neoplasms, Germ Cell and Embryonal | 25.4% |
| 28 | Neoplasms, Glandular and Epithelial | 25.4% |
| 29 | Germ Cell Cancer | 25.4% |
| 30 | Carcinosarcoma | 25% |
| 31 | Hemangiosarcoma | 25% |
| 32 | lymphangiosarcoma | 25% |
| 33 | Mastocytosis | 25% |
| 34 | Gastrointestinal Stromal Tumors | 24.6% |
| 35 | Mastocytoma | 24.3% |
| 36 | Mastocytosis, Systemic | 24.1% |
| 37 | Phyllodes Tumor | 22.6% |
| 38 | Lipoma | 22.6% |
| 39 | Myoma | 22.6% |
| 40 | Angiolipoma | 22.6% |
| 41 | Myelolipoma | 22.6% |
| 42 | Smooth Muscle Tumor | 22.6% |
| 43 | Desmoplastic Small Round Cell Tumor | 22.6% |
| 44 | Rhabdomyosarcoma | 22.3% |
| 45 | Sarcoma, Myeloid | 21.5% |
| 46 | Neuroectodermal Tumors | 19.8% |
| 47 | Alveolar rhabdomyosarcoma | 18.5% |
| 48 | Neurofibrosarcoma | 17.9% |
| 49 | Carcinoma 256, Walker | 17.7% |
| 50 | Neoplasms, Neuroepithelial | 17.1% |
| 51 | Gliomatosis cerebri | 17.1% |
| 52 | Histiocytic Disorders, Malignant | 16.9% |
| 53 | Rhabdomyoma | 16.8% |
| 54 | Hamartoma | 16.4% |
| 55 | Neoplasms, Hormone-Dependent | 16.4% |
| 56 | Neoplasms, Multiple Primary | 16.4% |
| 57 | Paraneoplastic Syndromes | 16.4% |
| 58 | Precancerous Conditions | 16.4% |
| 59 | Neoplasms, Second Primary | 16.4% |
| 60 | Sarcoma, Experimental | 15.7% |
| 61 | Dupuytren Contracture | 15.5% |
| 62 | Urticaria Pigmentosa | 15.2% |
| 63 | Adenoma | 14.8% |
| 64 | Ameloblastoma | 14.8% |
| 65 | Angiokeratoma | 14.8% |
| 66 | Carcinoma | 14.8% |
| 67 | Chordoma | 14.8% |
| 68 | Hemangioma | 14.8% |
| 69 | hemangiopericytoma | 14.8% |
| 70 | Lymphangioma | 14.8% |
| 71 | Mesenchymoma | 14.8% |
| 72 | Nevus | 14.8% |
| 73 | Teratoma | 14.8% |
| 74 | Hepatoblastoma | 14.8% |
| 75 | Mixed Tumor, Mullerian | 14.8% |
| 76 | Germinoma | 14.8% |
| 77 | Teratocarcinoma | 14.8% |
| 78 | Angiofibroma | 14.8% |
| 79 | Epithelioma | 14.8% |
| 80 | Sarcoma 180 | 14.6% |
| 81 | melanoma | 14.5% |
| 82 | Basal cell carcinoma | 12.9% |
| 83 | Carcinoma, Papillary | 12.9% |
| 84 | Squamous cell carcinoma | 12.9% |
| 85 | Craniopharyngioma | 12.9% |
| 86 | Cystadenoma | 12.9% |
| 87 | Mesothelioma | 12.9% |
| 88 | Neuroectodermal Tumor, Melanotic | 12.9% |
| 89 | Neuroendocrine Tumors | 12.9% |
| 90 | Lymphangioleiomyomatosis | 12.9% |
| 91 | Carcinoma, Basal Cell | 12.9% |
| 92 | Meningioma | 12.7% |
| 93 | Lymphoma | 12.6% |
| 94 | Endometrial Stromal Sarcoma | 12.5% |
| 95 | Carcinoma, Ehrlich Tumor | 12.2% |
| 96 | Dermoid Cyst | 12.2% |
| 97 | Carcinoma, Lewis Lung | 12.2% |
| 98 | Leukemia, Plasma Cell | 12.2% |
| 99 | Adenoma, Acidophil | 12% |
| 100 | Ganglioneuroma | 12% |
| 101 | Glioma | 12% |
| 102 | Malignant Glioma | 12% |
| 103 | Trophoblastic Neoplasms | 11.8% |
| 104 | Composite Lymphoma | 11.8% |
| 105 | Leukemia, Experimental | 11.7% |
| 106 | Cystadenocarcinoma | 11.2% |
| 107 | Mucoepidermoid Carcinoma | 11.2% |
| 108 | Medulloblastoma | 10.9% |
| 109 | Cyst | 10.8% |
| 110 | Neoplastic Processes | 10.8% |
| 111 | Neoplastic Syndromes, Hereditary | 10.8% |
| 112 | Pregnancy Complications, Neoplastic | 10.8% |
| 113 | Carcinoid Tumor | 10.8% |
| 114 | Neurilemmoma | 10.8% |
| 115 | Hutchinson's Melanotic Freckle | 10.8% |
| 116 | Melanoma, Amelanotic | 10.8% |
| 117 | Neoplasms, Experimental | 10.6% |
| 118 | Melanoma, Experimental | 10% |
| 119 | Plasmacytoma | 9.9% |
| 120 | Malignant histiocytosis | 9.8% |
| 121 | Leukemia L1210 | 9.8% |
| 122 | Leukemia P388 | 9.8% |
| 123 | Histiocytic sarcoma | 9.8% |
| 124 | Acanthoma | 9.8% |
| 125 | Adenocarcinoma | 9.7% |
| 126 | Carcinoma in Situ | 9.7% |
| 127 | Carcinoma, Transitional Cell | 9.7% |
| 128 | Dysgerminoma | 9.7% |
| 129 | Hemangioendothelioma | 9.7% |
| 130 | Neuroma | 9.7% |
| 131 | Papilloma | 9.7% |
| 132 | Pseudomyxoma Peritonei | 9.7% |
| 133 | Seminoma | 9.7% |
| 134 | Papillomatosis | 9.7% |
| 135 | Adenomatosis, Pulmonary | 9.7% |
| 136 | Adenomatous Polyps | 9.7% |
| 137 | Carcinoma, Large Cell | 9.7% |
| 138 | Carcinoma, Small Cell | 9.7% |
| 139 | Bowen's Disease | 9.6% |
| 140 | Paraganglioma | 9.6% |
| 141 | Astrocytoma | 9.5% |
| 142 | Ependymoma | 9.5% |
| 143 | oligodendroglioma | 9.5% |
| 144 | Ganglioglioma | 9.5% |
| 145 | gliosarcoma | 9.5% |
| 146 | Anaplastic astrocytoma | 9.5% |
| 147 | Anaplastic Oligodendroglioma | 9.5% |
| 148 | Leukemia, Radiation-Induced | 9.5% |
| 149 | Thymoma | 9% |
| 150 | Malignant Carcinoid Syndrome | 8.9% |
| 151 | Choriocarcinoma | 8.7% |
| 152 | Carcinoma, Lobular | 8.7% |
| 153 | Abdominal Neoplasms | 8.5% |
| 154 | Erythroplasia | 8.5% |
| 155 | Follicular cyst | 8.5% |
| 156 | Head and Neck Neoplasms | 8.5% |
| 157 | Mucocele | 8.5% |
| 158 | Pilonidal Cyst | 8.5% |
| 159 | Soft Tissue Neoplasms | 8.5% |
| 160 | Thoracic Neoplasms | 8.5% |
| 161 | Thyroglossal Cyst | 8.5% |
| 162 | Synovial Cyst | 8.5% |
| 163 | Aberrant Crypt Foci | 8.5% |
| 164 | Glioblastoma | 8.3% |
| 165 | Neuroblastoma | 8.3% |
| 166 | Glioblastoma Multiforme | 8.3% |
| 167 | Pheochromocytoma | 7.9% |
| 168 | Neoplasms, Radiation-Induced | 7.9% |
| 169 | Ganglioneuroblastoma | 7.7% |
| 170 | Multiple Endocrine Neoplasia | 7.4% |
| 171 | Hodgkin Disease | 7.3% |
| 172 | Lymphoma, Non-Hodgkin | 7.3% |
| 173 | Adenoid Cystic Carcinoma | 7.2% |
| 174 | Adenocarcinoma, Clear Cell | 7.2% |
| 175 | Cholangiocarcinoma | 7.2% |
| 176 | Cervical Intraepithelial Neoplasia | 7.2% |
| 177 | Hemangioblastoma | 7.2% |
| 178 | Lymphoma, Extranodal NK-T-Cell | 7.2% |
| 179 | Retinoblastoma | 7% |
| 180 | Paraneoplastic Encephalomyelitis | 6.8% |
| 181 | Mammary Neoplasms, Experimental | 6.7% |
| 182 | Carcinoid Heart Disease | 6.5% |
| 183 | Leukemia, Myelomonocytic, Chronic | 6.5% |
| 184 | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 6.5% |
| 185 | Lymphomatoid Granulomatosis | 6.2% |
| 186 | Digestive System Neoplasms | 6% |
| 187 | Endocrine Gland Neoplasms | 6% |
| 188 | Eye Neoplasms | 6% |
| 189 | Nervous System Neoplasms | 6% |
| 190 | Klatskin Tumor | 6% |
| 191 | Primary amyloidosis | 5.9% |
| 192 | Bone neoplasms | 5.7% |
| 193 | Leukoplakia | 5.7% |
| 194 | Lymphocele | 5.7% |
| 195 | Pancreatic Cyst | 5.7% |
| 196 | Skin Neoplasms | 5.7% |
| 197 | Hematologic Neoplasms | 5.7% |
| 198 | Nephroblastoma | 5.6% |
| 199 | Barrett Esophagus | 5.6% |
| 200 | Breast Cyst | 5.6% |
| 201 | Actinic keratosis | 5.6% |
| 202 | Mediastinal Cyst | 5.6% |
| 203 | Neoplasm Invasiveness | 5.6% |
| 204 | Neoplasm Metastasis | 5.6% |
| 205 | Neoplasm Recurrence, Local | 5.6% |
| 206 | Parovarian Cyst | 5.6% |
| 207 | Pericardial Cyst | 5.6% |
| 208 | Splenic Neoplasms | 5.6% |
| 209 | Thymic Cyst | 5.6% |
| 210 | Carcinogenesis | 5.6% |
| 211 | Myxoid cyst | 5.6% |
| 212 | Metastasis | 5.6% |
| 213 | Hepatocellular Adenoma | 5.2% |
| 214 | Hydatidiform Mole | 5.2% |
| 215 | Tuberous Sclerosis | 5.1% |
| 216 | Basal Cell Nevus Syndrome | 5.1% |
| 217 | Sturge-Weber Syndrome | 5% |
| 218 | Carcinoma, Pancreatic Ductal | 5% |
| 219 | Retroperitoneal Neoplasms | 4.9% |
| 220 | Hemangioma, Cavernous | 4.9% |
| 221 | Leukemia, T-Cell | 4.8% |
| 222 | Leukemia, B-Cell | 4.8% |
| 223 | Mesoblastic Nephroma | 4.8% |
| 224 | neurofibroma | 4.8% |
| 225 | Lymphoma, Follicular | 4.8% |
| 226 | T-Cell Lymphoma | 4.8% |
| 227 | Mantle cell lymphoma | 4.8% |
| 228 | Acoustic Neuroma | 4.8% |
| 229 | Leukemia, Myeloid, Chronic-Phase | 4.8% |
| 230 | Multiple Endocrine Neoplasia Type 1 | 4.4% |
| 231 | Prolactinoma | 4.3% |
| 232 | Growth Hormone-Secreting Pituitary Adenoma | 4.3% |
| 233 | Optic Nerve Glioma | 4.3% |
| 234 | Waldenstrom Macroglobulinemia | 4.2% |
| 235 | Multiple Myeloma | 4.2% |
| 236 | Vipoma | 4.2% |
| 237 | Corpus Luteum Cyst | 4.1% |
| 238 | Ovarian Cysts | 4.1% |
| 239 | Parathyroid Neoplasms | 4.1% |
| 240 | Peritoneal Neoplasms | 4.1% |
| 241 | Thyroid Neoplasm | 4.1% |
| 242 | Thyroid carcinoma | 4.1% |
| 243 | Liver Neoplasms, Experimental | 3.9% |
| 244 | granulosa cell tumor | 3.7% |
| 245 | Carcinoma, Ovarian Epithelial | 3.7% |
| 246 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3.6% |
| 247 | Leukemia, Large Granular Lymphocytic | 3.6% |
| 248 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3.6% |
| 249 | Lymphoma, T-Cell, Cutaneous | 3.6% |
| 250 | Lymphoma, AIDS-Related | 3.6% |
| 251 | Enteropathy-Associated T-Cell Lymphoma | 3.6% |
| 252 | Primary Effusion Lymphoma | 3.6% |
| 253 | Adenomatous Polyposis Coli | 3.5% |
| 254 | insulinoma | 3.4% |
| 255 | Pancreatic Neoplasm | 3.4% |
| 256 | Choledochal Cyst | 3.4% |
| 257 | Tracheal Neoplasms | 3.4% |
| 258 | Mouth Neoplasms | 3.4% |
| 259 | Central Nervous System Neoplasms | 3.4% |
| 260 | Vascular Neoplasms | 3.4% |
| 261 | Thymus Neoplasms | 3.4% |
| 262 | Genital Neoplasms, Female | 3.3% |
| 263 | Pancreatic Pseudocyst | 3.3% |
| 264 | Peutz-Jeghers Syndrome | 3.3% |
| 265 | Leukoplakia, Oral | 3.3% |
| 266 | Paraneoplastic Cerebellar Degeneration | 3.3% |
| 267 | Lymphatic Metastasis | 3.3% |
| 268 | Neoplasms, Unknown Primary | 3.3% |
| 269 | Leukemic Infiltration | 3.3% |
| 270 | Breast Neoplasms, Male | 3.3% |
| 271 | Neoplasm Micrometastasis | 3.3% |
| 272 | Triple Negative Breast Neoplasms | 3.3% |
| 273 | Adrenocortical carcinoma | 3.2% |
| 274 | Gastrinoma | 3.1% |
| 275 | Glucagonoma | 3.1% |
| 276 | Mycosis Fungoides | 3% |
| 277 | Lymphomatoid Papulosis | 3% |
| 278 | Plasmablastic lymphoma | 3% |
| 279 | Nasopharyngeal carcinoma | 2.9% |
| 280 | Leydig Cell Tumor | 2.9% |
| 281 | Esophageal Neoplasms | 2.7% |
| 282 | Renal Cell Carcinoma | 2.7% |
| 283 | Papillary Renal Cell Carcinoma | 2.7% |
| 284 | Limbic Encephalitis | 2.7% |
| 285 | Thyroid Nodule | 2.6% |
| 286 | Carcinoma, Endometrioid | 2.6% |
| 287 | Adrenal Gland Neoplasms | 2.6% |
| 288 | Gastrointestinal Neoplasms | 2.6% |
| 289 | Genital Neoplasms, Male | 2.6% |
| 290 | Liver neoplasms | 2.6% |
| 291 | Uveal Neoplasms | 2.6% |
| 292 | Denys-Drash Syndrome | 2.5% |
| 293 | Urologic Neoplasms | 2.5% |
| 294 | Sebaceous Gland Neoplasms | 2.5% |
| 295 | Spinal Neoplasms | 2.5% |
| 296 | Bone Marrow Neoplasms | 2.5% |
| 297 | Polycystic Ovary Syndrome | 2.4% |
| 298 | Burkitt Lymphoma | 2.4% |
| 299 | Lambert-Eaton Myasthenic Syndrome | 2.4% |
| 300 | Testicular Neoplasms | 2.4% |
| 301 | Meningeal Neoplasms | 2.2% |
| 302 | Opsoclonus-Myoclonus Syndrome | 2.1% |
| 303 | Sezary Syndrome | 2% |
| 304 | Xeroderma Pigmentosum | 1.9% |
| 305 | Myelitis, Transverse | 1.8% |
| 306 | Ear Neoplasms | 1.7% |
| 307 | Eyelid Neoplasms | 1.7% |
| 308 | Lung Neoplasms | 1.7% |
| 309 | Nose Neoplasms | 1.7% |
| 310 | Pleural Neoplasms | 1.7% |
| 311 | ovarian neoplasm | 1.7% |
| 312 | Cell Transformation, Viral | 1.6% |
| 313 | Brain Neoplasms | 1.6% |
| 314 | Salivary Gland Neoplasms | 1.6% |
| 315 | Spinal Cord Neoplasms | 1.6% |
| 316 | Tongue Neoplasms | 1.6% |
| 317 | Palatal Neoplasms | 1.6% |
| 318 | Uterine Neoplasms | 1.6% |
| 319 | Vaginal Neoplasms | 1.6% |
| 320 | Vulvar Neoplasms | 1.6% |
| 321 | Uterine Cancer | 1.6% |
| 322 | Fallopian Tube Neoplasms | 1.6% |
| 323 | Meningeal Carcinomatosis | 1.6% |
| 324 | Pituitary Adenoma | 1.5% |
| 325 | Pituitary Neoplasms | 1.5% |
| 326 | Pharyngeal Neoplasms | 1.4% |
| 327 | Central Nervous System Cysts | 1.3% |
| 328 | Bile Duct Neoplasms | 1.3% |
| 329 | gallbladder neoplasm | 1.3% |
| 330 | Intestinal Neoplasms | 1.3% |
| 331 | Penile Neoplasms | 1.3% |
| 332 | Prostatic Neoplasms | 1.3% |
| 333 | Stomach Neoplasms | 1.3% |
| 334 | Polycythemia Vera | 1.3% |
| 335 | Bronchial Neoplasms | 1.2% |
| 336 | Zollinger-Ellison syndrome | 1.2% |
| 337 | Multiple Pulmonary Nodules | 1.2% |
| 338 | Supratentorial Neoplasms | 1.2% |
| 339 | Endometrial Neoplasms | 1.2% |
| 340 | Laryngeal neoplasm | 1.1% |
| 341 | Bladder Neoplasm | 1.1% |
| 342 | Kidney Neoplasm | 1.1% |
| 343 | Ureteral Neoplasms | 1.1% |
| 344 | Urethral Neoplasms | 1.1% |
| 345 | Brain Stem Neoplasms | 1% |
| 346 | Hypopharyngeal Neoplasms | 1% |
| 347 | Pleural Effusion, Malignant | 1% |
| 348 | Hypopharyngeal Cancer | 1% |
| 349 | Parotid Neoplasms | 1% |
| 350 | Prostatic Neoplasms, Castration-Resistant | 1% |
| 351 | Nelson Syndrome | 1% |
| 352 | Choroid Plexus Papilloma | 0.9% |
| 353 | Cecal Neoplasms | 0.8% |
| 354 | Duodenal Neoplasms | 0.8% |
| 355 | Tonsillar Neoplasms | 0.8% |
| 356 | Cerebellar Neoplasms | 0.8% |
| 357 | Nasopharyngeal Neoplasms | 0.7% |
| 358 | Colorectal Neoplasms | 0.7% |
| 359 | Radicular Cyst | 0.7% |
| 360 | Appendiceal Neoplasms | 0.7% |
| 361 | Colonic Neoplasms | 0.7% |
| 362 | Rectal Neoplasms | 0.7% |
| 363 | Paranasal Sinus Neoplasms | 0.6% |
| 364 | Anus Neoplasms | 0.5% |
| 365 | Sigmoid Neoplasms | 0.5% |
| 366 | Maxillary Sinus Neoplasms | 0.5% |
